Vivek Podder, Research Fellow in Gynecological Oncology at Mount Sinai Medical Center of Florida, shared a post on LinkedIn about a paper he co-authored with colleagues published in Future Oncology:
“Happy to share our new publication in Future Oncology titled
‘Unmet needs and emerging therapeutics in low-grade serous ovarian carcinoma: from chemoresistance to precision medicine.’
This review explores how molecular insights and targeted therapies are offering new hope for patients with this rare, chemoresistant disease. The FDA accelerated approval of avutometinib plus defactinib for KRAS-mutated recurrent LGSOC marks a major step forward, while trials like GOG 3026 are expanding future treatment options (stay tuned as we share more exciting findings in a major oncology journal soon).
Grateful to collaboratively working with my supervisor Brian Slomovitz, and senior expert authors Erin Crane and Jubilee Brown.”
Title: Unmet needs and emerging therapeutics in low-grade serous ovarian carcinoma: from chemoresistance to precision medicine
Authors: Brian M. Slomovitz, Vivek Podder, Erin Crane, Jubilee Brown.
You can read the full article in Future Oncology.
More posts featuring Vivek Podder.